Fayez Sarofim & CO Eli Lilly & CO Transaction History

Fayez Sarofim & CO

$38.7 Billion
Q3 2024

A detailed history of Fayez Sarofim & CO transactions in Eli Lilly & CO stock. As of the latest transaction made, Fayez Sarofim & CO holds 367,875 shares of LLY stock, worth $286 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares

367,875

Previous 331,739 10.89%

Holding current value

$286 Million

Previous $300 Million 8.51%

% of portfolio

0.84%

Previous 0.82%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$772.14 - $960.02 $27.9 Million - $34.7 Million	36,136 Added 10.89%	367,875 $326 Million
Q2 2024 Aug 14, 2024	BUY	$724.87 - $909.04 $18.3 Million - $23 Million	25,270 Added 8.25%	331,739 $300 Million
Q1 2024 May 14, 2024	BUY	$592.2 - $792.28 $634,838 - $849,324	1,072 Added 0.35%	306,469 $238 Million
Q4 2023 Feb 14, 2024	BUY	$525.19 - $619.13 $19 Million - $22.4 Million	36,242 Added 13.47%	305,397 $178 Million
Q3 2023 Nov 14, 2023	BUY	$434.7 - $599.3 $15.6 Million - $21.6 Million	35,968 Added 15.42%	269,155 $145 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $11.9 Million - $15.9 Million	33,909 Added 17.02%	233,187 $109 Million
Q1 2023 May 11, 2023	BUY	$310.63 - $364.82 $16.9 Million - $19.8 Million	54,326 Added 37.48%	199,278 $68.4 Million
Q4 2022 Feb 13, 2023	BUY	$321.55 - $374.67 $35.5 Million - $41.4 Million	110,467 Added 320.33%	144,952 $53 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $126,004 - $143,594	425 Added 1.25%	34,485 $11.2 Million
Q2 2022 Aug 12, 2022	BUY	$278.73 - $327.27 $331,688 - $389,451	1,190 Added 3.62%	34,060 $11 Million
Q1 2022 May 16, 2022	BUY	$234.69 - $291.66 $269,424 - $334,825	1,148 Added 3.62%	32,870 $9.41 Million
Q4 2021 Feb 11, 2022	BUY	$224.85 - $279.04 $517,379 - $642,071	2,301 Added 7.82%	31,722 $8.76 Million
Q3 2021 Nov 15, 2021	SELL	$221.6 - $272.71 $34,569 - $42,542	-156 Reduced 0.53%	29,421 $6.8 Million
Q2 2021 Aug 13, 2021	BUY	$180.55 - $233.54 $341,961 - $442,324	1,894 Added 6.84%	29,577 $6.79 Million
Q1 2021 May 13, 2021	SELL	$164.32 - $212.72 $685,871 - $887,893	-4,174 Reduced 13.1%	27,683 $5.17 Million
Q4 2020 Feb 11, 2021	SELL	$130.46 - $172.63 $99,801 - $132,061	-765 Reduced 2.35%	31,857 $5.38 Million
Q3 2020 Nov 13, 2020	BUY	$146.22 - $169.13 $984,060 - $1.14 Million	6,730 Added 25.99%	32,622 $4.83 Million
Q2 2020 Aug 11, 2020	SELL	$136.42 - $164.18 $1.97 Million - $2.38 Million	-14,466 Reduced 35.84%	25,892 $4.25 Million
Q1 2020 May 12, 2020	BUY	$119.05 - $147.35 $45,953 - $56,877	386 Added 0.97%	40,358 $5.6 Million
Q4 2019 Feb 14, 2020	BUY	$106.92 - $132.43 $2.51 Million - $3.11 Million	23,450 Added 141.93%	39,972 $5.25 Million
Q3 2019 Nov 13, 2019	BUY	$106.79 - $116.16 $4,805 - $5,227	45 Added 0.27%	16,522 $1.85 Million
Q2 2019 Aug 09, 2019	SELL	$110.79 - $129.32 $6.6 Million - $7.71 Million	-59,606 Reduced 78.34%	16,477 $1.83 Million
Q1 2019 May 14, 2019	BUY	$111.31 - $131.02 $6.75 Million - $7.95 Million	60,686 Added 394.14%	76,083 $9.87 Million
Q4 2018 Feb 13, 2019	BUY	$105.9 - $118.64 $64,599 - $72,370	610 Added 4.13%	15,397 $1.78 Million
Q3 2018 Nov 14, 2018	BUY	$85.86 - $107.31 $42,930 - $53,655	500 Added 3.5%	14,787 $1.59 Million
Q2 2018 Aug 14, 2018	SELL	$75.7 - $86.88 $207,115 - $237,703	-2,736 Reduced 16.07%	14,287 $1.22 Million
Q1 2018 May 10, 2018	BUY	$74.21 - $87.6 $48,236 - $56,939	650 Added 3.97%	17,023 $1.32 Million
Q4 2017 Feb 13, 2018	SELL	$81.94 - $87.89 $1,147 - $1,230	-14 Reduced 0.09%	16,373 $1.38 Million
Q3 2017 Nov 08, 2017	BUY	$77.07 - $85.54 $1.26 Million - $1.4 Million	16,387	16,387 $1.4 Million

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $740B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.

Account